Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan
BACKGROUND: The WHO recommends the use of bedaquiline (BDQ) in longer, as well as shorter, multidrug-resistant TB (MDR-TB) treatment regimens. However, resistance to this new drug is now emerging. We aimed to describe the characteristics of patients in Karakalpakstan, Uzbekistan, who were treated fo...
Gespeichert in:
| Veröffentlicht in: | The international journal of tuberculosis and lung disease 2022-07, Vol.26 (7), p.658-663 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 663 |
|---|---|
| container_issue | 7 |
| container_start_page | 658 |
| container_title | The international journal of tuberculosis and lung disease |
| container_volume | 26 |
| creator | Nair, P. Hasan, T. Zaw, K. K. Allamuratova, S. Ismailov, A. Mendonca, P. Bekbaev, Z. Parpieva, N. Singh, J. Sitali, N. Bermudez-Aza, E. Sinha, A. |
| description | BACKGROUND: The WHO recommends the use of bedaquiline (BDQ) in longer, as well as shorter, multidrug-resistant TB (MDR-TB) treatment regimens. However, resistance to this new drug is now emerging. We aimed to describe the characteristics of patients in Karakalpakstan, Uzbekistan,
who were treated for MDR-TB and acquired BDQ resistance during treatment.METHODS: We performed a retrospective study of routinely collected data for patients treated for MDR-TB in Karakalpakstan between January 2015 and December 2020. We included patients on BDQ-containing regimens
with baseline susceptibility to BDQ who developed BDQ resistance at any point after treatment initiation. Patients resistant to BDQ at baseline or with no confirmed susceptibility to BDQ at baseline were excluded.RESULTS: Of the 523 patients who received BDQ-containing regimens
during the study period, BDQ resistance was detected in 31 patients (5.9%); 20 patients were excluded-16 with no prior confirmation of BDQ susceptibility and 4 who were resistant at baseline. Eleven patients with acquired BDQ resistance were identified. We discuss demographic variables,
resistance profiles, treatment-related variables and risk factors for unfavourable outcomes for these patients.CONCLUSION: Our programmatic data demonstrated the acquisition of BDQ resistance during or subsequent to receiving a BDQ-containing regimen in a patient cohort from Uzbekistan.
We highlight the need for individualised treatment regimens with optimised clinical and laboratory follow up to prevent resistance acquisition. |
| doi_str_mv | 10.5588/ijtld.21.0631 |
| format | Article |
| fullrecord | <record><control><sourceid>pubtec_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2682785358</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ingid>iuatld/ijtld/2022/00000026/00000007/art00013</ingid><sourcerecordid>iuatld/ijtld/2022/00000026/00000007/art00013</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-e226349b5a23a1defb861a7d2ecd769e0e39b599a3e5b2ff3c227f634cef9f923</originalsourceid><addsrcrecordid>eNp1kd-L1DAQx4so3nn66HvBFx_smkyapnlQOM6feCCC9zxM0-ma3W67l7QH3l9vursoCuYlQ-aTD5N8s-y5FCut6_q130x9uwK5EpWSD7JzWUtdGAviYaoFmEIZac-yJzFuhAAppXmcnSltqtqCPs_eXLrb2Qdu84ZbSmXvB84DRx8nGhznfsi_UKAt9XvaLmev8pv7hreH_tPsUUd95Gen_SK7-fD--9Wn4vrrx89Xl9eFK7WZCgaoVGkbTaBIttw1dSXJtMCuNZVlwSo1rSXFuoGuUw7AdOmK4852FtRF9vbo3c_NjlvHwxSox33wOwo_cSSPf3cG_wPX4x1aMGBUnQQvT4Iw3s4cJ9z56LjvaeBxjghVDabWSi_oi3_QzTiHIT3vQNn06WWZqOJIuTDGGLj7PYwUuASDh2AQJC7BJP7bkffDOs1If6TeoZ9pYZe4lrTwDqrBIAgAYUQSlAow_RrN_YQTBVzfY5QqOd_9z3kUnkZIHhSHBdWpEAYpTGlPml9Od7JR</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2682958844</pqid></control><display><type>article</type><title>Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan</title><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Nair, P. ; Hasan, T. ; Zaw, K. K. ; Allamuratova, S. ; Ismailov, A. ; Mendonca, P. ; Bekbaev, Z. ; Parpieva, N. ; Singh, J. ; Sitali, N. ; Bermudez-Aza, E. ; Sinha, A.</creator><creatorcontrib>Nair, P. ; Hasan, T. ; Zaw, K. K. ; Allamuratova, S. ; Ismailov, A. ; Mendonca, P. ; Bekbaev, Z. ; Parpieva, N. ; Singh, J. ; Sitali, N. ; Bermudez-Aza, E. ; Sinha, A.</creatorcontrib><description>BACKGROUND: The WHO recommends the use of bedaquiline (BDQ) in longer, as well as shorter, multidrug-resistant TB (MDR-TB) treatment regimens. However, resistance to this new drug is now emerging. We aimed to describe the characteristics of patients in Karakalpakstan, Uzbekistan,
who were treated for MDR-TB and acquired BDQ resistance during treatment.METHODS: We performed a retrospective study of routinely collected data for patients treated for MDR-TB in Karakalpakstan between January 2015 and December 2020. We included patients on BDQ-containing regimens
with baseline susceptibility to BDQ who developed BDQ resistance at any point after treatment initiation. Patients resistant to BDQ at baseline or with no confirmed susceptibility to BDQ at baseline were excluded.RESULTS: Of the 523 patients who received BDQ-containing regimens
during the study period, BDQ resistance was detected in 31 patients (5.9%); 20 patients were excluded-16 with no prior confirmation of BDQ susceptibility and 4 who were resistant at baseline. Eleven patients with acquired BDQ resistance were identified. We discuss demographic variables,
resistance profiles, treatment-related variables and risk factors for unfavourable outcomes for these patients.CONCLUSION: Our programmatic data demonstrated the acquisition of BDQ resistance during or subsequent to receiving a BDQ-containing regimen in a patient cohort from Uzbekistan.
We highlight the need for individualised treatment regimens with optimised clinical and laboratory follow up to prevent resistance acquisition.</description><identifier>ISSN: 1027-3719</identifier><identifier>EISSN: 1815-7920</identifier><identifier>DOI: 10.5588/ijtld.21.0631</identifier><identifier>PMID: 35768925</identifier><language>eng</language><publisher>Paris: International Union Against Tuberculosis and Lung Disease</publisher><subject>antibiotic resistance ; Data collection ; Demographic variables ; Drug Resistance ; Mdr-Tb ; Multidrug resistance ; Multidrug resistant organisms ; Original ; Patients ; Risk analysis ; Risk factors ; Xdr-Tb</subject><ispartof>The international journal of tuberculosis and lung disease, 2022-07, Vol.26 (7), p.658-663</ispartof><rights>Copyright International Union against Tuberculosis and Lung Disease (IUATLD) Jul 2022</rights><rights>2022 The Union 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-e226349b5a23a1defb861a7d2ecd769e0e39b599a3e5b2ff3c227f634cef9f923</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272738/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272738/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Nair, P.</creatorcontrib><creatorcontrib>Hasan, T.</creatorcontrib><creatorcontrib>Zaw, K. K.</creatorcontrib><creatorcontrib>Allamuratova, S.</creatorcontrib><creatorcontrib>Ismailov, A.</creatorcontrib><creatorcontrib>Mendonca, P.</creatorcontrib><creatorcontrib>Bekbaev, Z.</creatorcontrib><creatorcontrib>Parpieva, N.</creatorcontrib><creatorcontrib>Singh, J.</creatorcontrib><creatorcontrib>Sitali, N.</creatorcontrib><creatorcontrib>Bermudez-Aza, E.</creatorcontrib><creatorcontrib>Sinha, A.</creatorcontrib><title>Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan</title><title>The international journal of tuberculosis and lung disease</title><description>BACKGROUND: The WHO recommends the use of bedaquiline (BDQ) in longer, as well as shorter, multidrug-resistant TB (MDR-TB) treatment regimens. However, resistance to this new drug is now emerging. We aimed to describe the characteristics of patients in Karakalpakstan, Uzbekistan,
who were treated for MDR-TB and acquired BDQ resistance during treatment.METHODS: We performed a retrospective study of routinely collected data for patients treated for MDR-TB in Karakalpakstan between January 2015 and December 2020. We included patients on BDQ-containing regimens
with baseline susceptibility to BDQ who developed BDQ resistance at any point after treatment initiation. Patients resistant to BDQ at baseline or with no confirmed susceptibility to BDQ at baseline were excluded.RESULTS: Of the 523 patients who received BDQ-containing regimens
during the study period, BDQ resistance was detected in 31 patients (5.9%); 20 patients were excluded-16 with no prior confirmation of BDQ susceptibility and 4 who were resistant at baseline. Eleven patients with acquired BDQ resistance were identified. We discuss demographic variables,
resistance profiles, treatment-related variables and risk factors for unfavourable outcomes for these patients.CONCLUSION: Our programmatic data demonstrated the acquisition of BDQ resistance during or subsequent to receiving a BDQ-containing regimen in a patient cohort from Uzbekistan.
We highlight the need for individualised treatment regimens with optimised clinical and laboratory follow up to prevent resistance acquisition.</description><subject>antibiotic resistance</subject><subject>Data collection</subject><subject>Demographic variables</subject><subject>Drug Resistance</subject><subject>Mdr-Tb</subject><subject>Multidrug resistance</subject><subject>Multidrug resistant organisms</subject><subject>Original</subject><subject>Patients</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Xdr-Tb</subject><issn>1027-3719</issn><issn>1815-7920</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kd-L1DAQx4so3nn66HvBFx_smkyapnlQOM6feCCC9zxM0-ma3W67l7QH3l9vursoCuYlQ-aTD5N8s-y5FCut6_q130x9uwK5EpWSD7JzWUtdGAviYaoFmEIZac-yJzFuhAAppXmcnSltqtqCPs_eXLrb2Qdu84ZbSmXvB84DRx8nGhznfsi_UKAt9XvaLmev8pv7hreH_tPsUUd95Gen_SK7-fD--9Wn4vrrx89Xl9eFK7WZCgaoVGkbTaBIttw1dSXJtMCuNZVlwSo1rSXFuoGuUw7AdOmK4852FtRF9vbo3c_NjlvHwxSox33wOwo_cSSPf3cG_wPX4x1aMGBUnQQvT4Iw3s4cJ9z56LjvaeBxjghVDabWSi_oi3_QzTiHIT3vQNn06WWZqOJIuTDGGLj7PYwUuASDh2AQJC7BJP7bkffDOs1If6TeoZ9pYZe4lrTwDqrBIAgAYUQSlAow_RrN_YQTBVzfY5QqOd_9z3kUnkZIHhSHBdWpEAYpTGlPml9Od7JR</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Nair, P.</creator><creator>Hasan, T.</creator><creator>Zaw, K. K.</creator><creator>Allamuratova, S.</creator><creator>Ismailov, A.</creator><creator>Mendonca, P.</creator><creator>Bekbaev, Z.</creator><creator>Parpieva, N.</creator><creator>Singh, J.</creator><creator>Sitali, N.</creator><creator>Bermudez-Aza, E.</creator><creator>Sinha, A.</creator><general>International Union Against Tuberculosis and Lung Disease</general><general>International Union against Tuberculosis and Lung Disease (IUATLD)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220701</creationdate><title>Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan</title><author>Nair, P. ; Hasan, T. ; Zaw, K. K. ; Allamuratova, S. ; Ismailov, A. ; Mendonca, P. ; Bekbaev, Z. ; Parpieva, N. ; Singh, J. ; Sitali, N. ; Bermudez-Aza, E. ; Sinha, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-e226349b5a23a1defb861a7d2ecd769e0e39b599a3e5b2ff3c227f634cef9f923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>antibiotic resistance</topic><topic>Data collection</topic><topic>Demographic variables</topic><topic>Drug Resistance</topic><topic>Mdr-Tb</topic><topic>Multidrug resistance</topic><topic>Multidrug resistant organisms</topic><topic>Original</topic><topic>Patients</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Xdr-Tb</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nair, P.</creatorcontrib><creatorcontrib>Hasan, T.</creatorcontrib><creatorcontrib>Zaw, K. K.</creatorcontrib><creatorcontrib>Allamuratova, S.</creatorcontrib><creatorcontrib>Ismailov, A.</creatorcontrib><creatorcontrib>Mendonca, P.</creatorcontrib><creatorcontrib>Bekbaev, Z.</creatorcontrib><creatorcontrib>Parpieva, N.</creatorcontrib><creatorcontrib>Singh, J.</creatorcontrib><creatorcontrib>Sitali, N.</creatorcontrib><creatorcontrib>Bermudez-Aza, E.</creatorcontrib><creatorcontrib>Sinha, A.</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The international journal of tuberculosis and lung disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nair, P.</au><au>Hasan, T.</au><au>Zaw, K. K.</au><au>Allamuratova, S.</au><au>Ismailov, A.</au><au>Mendonca, P.</au><au>Bekbaev, Z.</au><au>Parpieva, N.</au><au>Singh, J.</au><au>Sitali, N.</au><au>Bermudez-Aza, E.</au><au>Sinha, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan</atitle><jtitle>The international journal of tuberculosis and lung disease</jtitle><date>2022-07-01</date><risdate>2022</risdate><volume>26</volume><issue>7</issue><spage>658</spage><epage>663</epage><pages>658-663</pages><issn>1027-3719</issn><eissn>1815-7920</eissn><abstract>BACKGROUND: The WHO recommends the use of bedaquiline (BDQ) in longer, as well as shorter, multidrug-resistant TB (MDR-TB) treatment regimens. However, resistance to this new drug is now emerging. We aimed to describe the characteristics of patients in Karakalpakstan, Uzbekistan,
who were treated for MDR-TB and acquired BDQ resistance during treatment.METHODS: We performed a retrospective study of routinely collected data for patients treated for MDR-TB in Karakalpakstan between January 2015 and December 2020. We included patients on BDQ-containing regimens
with baseline susceptibility to BDQ who developed BDQ resistance at any point after treatment initiation. Patients resistant to BDQ at baseline or with no confirmed susceptibility to BDQ at baseline were excluded.RESULTS: Of the 523 patients who received BDQ-containing regimens
during the study period, BDQ resistance was detected in 31 patients (5.9%); 20 patients were excluded-16 with no prior confirmation of BDQ susceptibility and 4 who were resistant at baseline. Eleven patients with acquired BDQ resistance were identified. We discuss demographic variables,
resistance profiles, treatment-related variables and risk factors for unfavourable outcomes for these patients.CONCLUSION: Our programmatic data demonstrated the acquisition of BDQ resistance during or subsequent to receiving a BDQ-containing regimen in a patient cohort from Uzbekistan.
We highlight the need for individualised treatment regimens with optimised clinical and laboratory follow up to prevent resistance acquisition.</abstract><cop>Paris</cop><pub>International Union Against Tuberculosis and Lung Disease</pub><pmid>35768925</pmid><doi>10.5588/ijtld.21.0631</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1027-3719 |
| ispartof | The international journal of tuberculosis and lung disease, 2022-07, Vol.26 (7), p.658-663 |
| issn | 1027-3719 1815-7920 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2682785358 |
| source | PubMed Central; Alma/SFX Local Collection |
| subjects | antibiotic resistance Data collection Demographic variables Drug Resistance Mdr-Tb Multidrug resistance Multidrug resistant organisms Original Patients Risk analysis Risk factors Xdr-Tb |
| title | Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T08%3A02%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubtec_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acquired%20bedaquiline%20resistance%20in%20Karakalpakstan,%20Uzbekistan&rft.jtitle=The%20international%20journal%20of%20tuberculosis%20and%20lung%20disease&rft.au=Nair,%20P.&rft.date=2022-07-01&rft.volume=26&rft.issue=7&rft.spage=658&rft.epage=663&rft.pages=658-663&rft.issn=1027-3719&rft.eissn=1815-7920&rft_id=info:doi/10.5588/ijtld.21.0631&rft_dat=%3Cpubtec_proqu%3Eiuatld/ijtld/2022/00000026/00000007/art00013%3C/pubtec_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2682958844&rft_id=info:pmid/35768925&rft_ingid=iuatld/ijtld/2022/00000026/00000007/art00013&rfr_iscdi=true |